🚀 VC round data is live in beta, check it out!
SK Biopharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for SK Biopharmaceuticals and similar public comparables like NewMarket, Lundbeck, Chongqing Zhifei, CRISPR Therapeutics and more.
SK Biopharmaceuticals Overview
About SK Biopharmaceuticals
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in the research and development of new drugs for the treatment of central nervous system (CNS) disorders. The company is also researching the development of drugs to treat brain tumors, including metastatic tumors. Its drug pipeline includes Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and more.
Founded
2011
HQ
Employees
265
Website
Sectors
Financials (LTM)
EV
$6B
SK Biopharmaceuticals Financials
SK Biopharmaceuticals reported last 12-month revenue of $507M and EBITDA of $163M.
In the same LTM period, SK Biopharmaceuticals generated $476M in gross profit, $163M in EBITDA, and $180M in net income.
Revenue (LTM)
SK Biopharmaceuticals P&L
In the most recent fiscal year, SK Biopharmaceuticals reported revenue of $369M and EBITDA of $68M.
SK Biopharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $507M | XXX | $369M | XXX | XXX | XXX |
| Gross Profit | $476M | XXX | $340M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | $163M | XXX | $68M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $180M | XXX | $162M | XXX | XXX | XXX |
| Net Margin | 36% | XXX | 44% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SK Biopharmaceuticals Stock Performance
SK Biopharmaceuticals has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
SK Biopharmaceuticals' stock price is $75.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | 0.0% | XXX | XXX | XXX | $2.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSK Biopharmaceuticals Valuation Multiples
SK Biopharmaceuticals trades at 11.3x EV/Revenue multiple, and 35.3x EV/EBITDA.
EV / Revenue (LTM)
SK Biopharmaceuticals Financial Valuation Multiples
As of March 9, 2026, SK Biopharmaceuticals has market cap of $6B and EV of $6B.
Equity research analysts estimate SK Biopharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SK Biopharmaceuticals has a P/E ratio of 32.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 11.3x | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBITDA | 35.3x | XXX | 84.7x | XXX | XXX | XXX |
| EV/EBIT | 37.5x | XXX | 88.5x | XXX | XXX | XXX |
| EV/Gross Profit | 12.1x | XXX | 16.9x | XXX | XXX | XXX |
| P/E | 32.7x | XXX | 36.3x | XXX | XXX | XXX |
| EV/FCF | 38.9x | XXX | 104.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SK Biopharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SK Biopharmaceuticals Margins & Growth Rates
SK Biopharmaceuticals' revenue in the last 12 month grew by 27%.
SK Biopharmaceuticals' revenue per employee in the last FY averaged $1.9M.
SK Biopharmaceuticals' rule of 40 is 59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SK Biopharmaceuticals' rule of X is 100% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
SK Biopharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | 121% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 59% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 100% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 30% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SK Biopharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| NewMarket | XXX | XXX | XXX | XXX | XXX | XXX |
| Lundbeck | XXX | XXX | XXX | XXX | XXX | XXX |
| Chongqing Zhifei | XXX | XXX | XXX | XXX | XXX | XXX |
| CRISPR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Caris Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SK Biopharmaceuticals M&A Activity
SK Biopharmaceuticals acquired XXX companies to date.
Last acquisition by SK Biopharmaceuticals was on XXXXXXXX, XXXXX. SK Biopharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SK Biopharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSK Biopharmaceuticals Investment Activity
SK Biopharmaceuticals invested in XXX companies to date.
SK Biopharmaceuticals made its latest investment on XXXXXXXX, XXXXX. SK Biopharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SK Biopharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SK Biopharmaceuticals
| When was SK Biopharmaceuticals founded? | SK Biopharmaceuticals was founded in 2011. |
| Where is SK Biopharmaceuticals headquartered? | SK Biopharmaceuticals is headquartered in South Korea. |
| How many employees does SK Biopharmaceuticals have? | As of today, SK Biopharmaceuticals has over 265 employees. |
| Who is the CEO of SK Biopharmaceuticals? | SK Biopharmaceuticals' CEO is Dong-Hoon Lee. |
| Is SK Biopharmaceuticals publicly listed? | Yes, SK Biopharmaceuticals is a public company listed on Korea Exchange. |
| What is the stock symbol of SK Biopharmaceuticals? | SK Biopharmaceuticals trades under 326030 ticker. |
| When did SK Biopharmaceuticals go public? | SK Biopharmaceuticals went public in 2020. |
| Who are competitors of SK Biopharmaceuticals? | SK Biopharmaceuticals main competitors are NewMarket, Lundbeck, Chongqing Zhifei, CRISPR Therapeutics. |
| What is the current market cap of SK Biopharmaceuticals? | SK Biopharmaceuticals' current market cap is $6B. |
| What is the current revenue of SK Biopharmaceuticals? | SK Biopharmaceuticals' last 12 months revenue is $507M. |
| What is the current revenue growth of SK Biopharmaceuticals? | SK Biopharmaceuticals revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of SK Biopharmaceuticals? | Current revenue multiple of SK Biopharmaceuticals is 11.3x. |
| Is SK Biopharmaceuticals profitable? | Yes, SK Biopharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SK Biopharmaceuticals? | SK Biopharmaceuticals' last 12 months EBITDA is $163M. |
| What is SK Biopharmaceuticals' EBITDA margin? | SK Biopharmaceuticals' last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of SK Biopharmaceuticals? | Current EBITDA multiple of SK Biopharmaceuticals is 35.3x. |
| What is the current FCF of SK Biopharmaceuticals? | SK Biopharmaceuticals' last 12 months FCF is $148M. |
| What is SK Biopharmaceuticals' FCF margin? | SK Biopharmaceuticals' last 12 months FCF margin is 29%. |
| What is the current EV/FCF multiple of SK Biopharmaceuticals? | Current FCF multiple of SK Biopharmaceuticals is 38.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.